What Is Retatrutide? Trial Results, Risks, and Whether You Can Get It Yet
Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.
RETATRUTIDE REALITY CHECK — LAST VERIFIED APRIL 12, 2026 · Sources: FDA, Eli Lilly, NEJM, Nature Medicine, ClinicalTrials.gov
Sources: Editorial Standards · Affiliate Disclosure · Next audit: May 12, 2026
So what is retatrutide? It is an investigational weight-loss injection from Eli Lilly that targets three hormone receptors at once — GLP-1, GIP, and glucagon — instead of the one or two targeted by every obesity drug currently on the market. In Phase 3 clinical trials, participants on retatrutide lost an average of 28.7% of their body weight over 68 weeks, roughly 71 pounds. That is the highest weight loss ever recorded in a Phase 3 obesity drug trial.
Here is what most headlines skip: retatrutide is not FDA-approved, not available at any pharmacy, and not legally sold online. The only legitimate access is through Eli Lilly's registered clinical trials. Anyone selling “retatrutide” today is selling an unregulated, illegal product — and the FDA has publicly warned against it.
The weight-loss medication landscape in 2026 looks dramatically different than it did even six months ago. Wegovy HD, oral Wegovy, Zepbound, and Foundayo are all FDA-approved and available now. Retatrutide promises an even higher ceiling — but it is still years away from your pharmacy. We pulled from every official source we could verify — Eli Lilly's FAQ and investor releases, peer-reviewed trials in the NEJM and Nature Medicine, and FDA press releases — to build the clearest picture available.
Retatrutide Reality Check: Everything in One Place
Every row below is sourced and labeled by evidence quality so you know how much weight to put on each claim.
| What you want to know | Verified answer | Evidence tier | What it means right now |
|---|---|---|---|
| What is it? | Investigational once-weekly injectable triple agonist activating GIP, GLP-1, and glucagon receptors | Eli Lilly official FAQ | Not "another GLP-1" — it uses three metabolic pathways |
| Is "GLP-3" a real term? | No. "GLP-3" is social media shorthand, not a scientific classification. The correct term is "triple hormone receptor agonist" | Eli Lilly official FAQ | If a source calls it "GLP-3," treat the rest of their claims with extra skepticism |
| Is it FDA-approved? | No. No regulatory agency worldwide has approved it | Eli Lilly FAQ; FDA | No prescriptions, no pharmacies, no legitimate retail sales |
| Can you buy it legally? | Legitimate access is limited to Eli Lilly's registered clinical trials | Eli Lilly official FAQ | "Where can I buy it?" is the wrong question right now |
| Can it be compounded? | No. FDA states retatrutide cannot be used in compounding under federal law | FDA enforcement page | Different from semaglutide and tirzepatide, which are FDA-approved drugs with a different compounding legal history |
| Strongest peer-reviewed weight loss | 24.2% mean body-weight reduction at 48 weeks (Phase 2, 12 mg, 338 participants) | Peer-reviewed — Jastreboff et al., NEJM 2023 | Strong signal from an earlier-stage study |
| Strongest Phase 3 weight loss | 28.7% at 68 weeks (TRIUMPH-4, 12 mg, 445 participants) | Lilly topline press release, Dec 11, 2025 | Record-breaking, but not yet published in a peer-reviewed journal |
| Latest diabetes result | A1C reduction of 1.7–2.0% and up to 16.8% weight loss at 40 weeks (TRANSCEND-T2D-1, 537 participants) | Lilly topline press release, Mar 19, 2026 | Competitive with tirzepatide; weight loss had not plateaued |
| Most notable safety signal | Dysesthesia in 20.9% at 12 mg in TRIUMPH-4; 2.3–4.5% in TRANSCEND-T2D-1. GI side effects consistent with other GLP-1 drugs | Eli Lilly Phase 3 topline data | Higher-dose GLP-1 dysesthesia also emerges with Wegovy HD (22% at 7.2 mg) — not exclusive to retatrutide |
| What does it cost? | No public price announced | Drugs.com; Eli Lilly | Any page quoting a consumer price is speculating |
| When might it be available? | Additional Phase 3 results expected 2026; no filing date confirmed. Analyst estimates: late 2027 at earliest | Eli Lilly official FAQ | Not an officially confirmed timeline |
Sources: Eli Lilly FAQ (lilly.com), investor releases (investor.lilly.com), FDA (fda.gov), Jastreboff et al. NEJM 2023. All checked April 12, 2026.
What Is Retatrutide?
Retatrutide (also identified as LY3437943) is Eli Lilly's investigational once-weekly triple hormone receptor agonist. It activates three receptors — GIP, GLP-1, and glucagon — making it the first drug of its kind to reach Phase 3 clinical trials. It has no FDA approval, no brand name yet, and no legitimate retail path outside of clinical trials.
You may have heard it called “GLP-3” or “triple G” on social media. Neither is a real medical term. Eli Lilly's own FAQ confirms that “GLP-3” is scientifically inaccurate — the correct description is a triple hormone receptor agonist.
Eli Lilly is the same company behind Zepbound (tirzepatide) and Foundayo (orforglipron). Retatrutide is designed to be their next-generation option — building on the dual-agonist foundation of tirzepatide by adding a third receptor target.
Why Is Retatrutide Suddenly Everywhere?
Three things happened in rapid succession, and each one amplified the next.
The Phase 2 result that started it
In 2023, the New England Journal of Medicine published Eli Lilly's Phase 2 obesity trial. Participants on the highest dose lost 24.2% of their body weight at 48 weeks — and the weight-loss curve had not flattened, meaning longer treatment would produce even greater reductions. Those numbers beat everything semaglutide and tirzepatide had shown in their own trials.
The Phase 3 result that blew it up
On December 11, 2025, Lilly released topline results from TRIUMPH-4. Average weight loss hit 28.7% at 68 weeks — roughly 71 pounds. That number broke every Phase 3 record. Reddit dubbed it “the Godzilla of weight loss.” Headlines ran everywhere.
The diabetes data that confirmed the pattern
On March 19, 2026, TRANSCEND-T2D-1 reported A1C reductions of up to 2.0% and weight loss of 16.8% at 40 weeks, with no plateau in sight. Two successful Phase 3 readouts across different populations told the market this was not a one-trial fluke.
The problem: attention outran access. Retatrutide is investigational. The detailed TRIUMPH-4 data has not been published in a peer-reviewed journal. Seven more Phase 3 readouts are expected throughout 2026. And people are already searching “where to buy retatrutide” — which has no safe answer right now.
What real people are asking online: “What is up with retatrutide?” · “Anyone here planning on switching to reta when it drops?” · “When will retatrutide be available by prescription in the US?” · “Does anyone recommend anywhere selling retatrutide yet?”
How Does Retatrutide Work?
Retatrutide is the first drug to activate three hormone receptors involved in appetite, metabolism, and blood sugar at the same time.
GLP-1 (glucagon-like peptide-1): the appetite brake
The same receptor targeted by semaglutide (Wegovy, Ozempic). It suppresses appetite, slows stomach emptying, and improves insulin release after meals. This is the foundation of every currently approved GLP-1 weight-loss drug.
GIP (glucose-dependent insulinotropic polypeptide): the metabolic amplifier
The second receptor targeted by tirzepatide (Zepbound, Mounjaro). It enhances insulin sensitivity and fat metabolism, and appears to amplify GLP-1's weight-loss effects. This is why tirzepatide produces more weight loss than semaglutide alone.
Glucagon: the third lever — the differentiator
No currently approved obesity drug directly targets this receptor. Glucagon promotes fat burning in the liver and may increase resting energy expenditure. This third pathway likely explains why retatrutide produced an 86% reduction in liver fat in Phase 2 substudies — substantially more than semaglutide (~50%) or tirzepatide (~47%).
It is administered as a once-weekly subcutaneous injection, starting at 2 mg and increasing every 4 weeks to a target dose of 4, 9, or 12 mg. Phase 2 data showed this gradual titration meaningfully reduces GI side effects compared to starting at a higher dose.
What scientists still do not fully know:
The precise interactions between all three receptors at different doses are still being studied. Whether a lower maintenance dose (4 mg) can preserve most weight loss with fewer side effects is being tested in the ongoing TRIUMPH program, with results expected later in 2026.
What Do the Latest Studies Actually Show?
Not all data is equal. A peer-reviewed study in the New England Journal of Medicine carries more weight than a company press release. Both matter, but the distinction tells you how much confidence to place in each number.
Phase 2 obesity trial — peer-reviewed (NEJM 2023)
338 adults with obesity or overweight (without diabetes) across U.S. sites, over 48 weeks. Published in the NEJM (Jastreboff et al., 2023), independently reviewed before publication.
| Dose | Average weight loss at 48 weeks |
|---|---|
| 1 mg | 8.7% |
| 4 mg (slow escalation) | 17.1% |
| 8 mg (slow escalation) | 22.8% |
| 12 mg | 24.2% |
| Placebo | 2.1% |
At 12 mg, 83% of participants achieved at least 15% weight loss. Weight loss had not plateaued at 48 weeks. Source: Jastreboff AM et al., NEJM 2023.
Liver fat substudy — peer-reviewed (Nature Medicine 2024)
Pre-specified substudy in participants with metabolic dysfunction-associated steatotic liver disease (MASLD):
| Dose | Liver fat reduction at 48 weeks | Achieved normal liver fat (<5%) |
|---|---|---|
| 8 mg | 81.7% | 89% |
| 12 mg | 86.0% | 93% |
| Placebo | 4.6% | 0% |
That 86% reduction is the largest reported for any pharmacological intervention in MASLD. A dedicated Phase 3 liver disease trial (SYNERGY) is now underway. Source: Sanyal AJ et al., Nature Medicine 2024.
TRIUMPH-4 — Phase 3 (December 2025, topline)
First Phase 3 readout. 445 adults with obesity and knee osteoarthritis:
| Dose | Weight loss at 68 weeks | WOMAC pain reduction |
|---|---|---|
| 9 mg | 26.4% | 75.5% |
| 12 mg | 28.7% (avg. 71.2 lbs) | 75.8% |
| Placebo | 2.1% | 40.3% |
58.6% of participants on 12 mg achieved at least 25% weight loss. More than 1 in 8 retatrutide-treated participants were completely pain-free at study end. Source: Eli Lilly press release, Dec 11, 2025. Evidence tier: Company topline — full peer-reviewed publication pending.
TRANSCEND-T2D-1 — Phase 3 (March 2026, topline)
First Phase 3 diabetes readout. 537 adults with type 2 diabetes:
| Dose | A1C reduction at 40 weeks | Weight loss at 40 weeks |
|---|---|---|
| 4 mg | 1.7% | 11.5% |
| 9 mg | 2.0% | 14.1% |
| 12 mg | 1.9% | 16.8% (avg. 36.6 lbs) |
| Placebo | 0.8% | 2.5% |
Weight loss had not plateaued at 40 weeks in any dose group. Detailed results expected at the American Diabetes Association Scientific Sessions, June 2026. Source: Eli Lilly press release, March 19, 2026. Evidence tier: Company topline.
The retatrutide trial landscape — what is still running
| Trial family | Indications studied | Completed readouts |
|---|---|---|
| TRIUMPH | Obesity/overweight, knee osteoarthritis, obstructive sleep apnea, cardiovascular disease, maintenance dosing (including 4 mg dose) | TRIUMPH-4 ✅ (Dec 2025) |
| TRANSCEND | Type 2 diabetes (3 trials, 2,050+ participants across program) | TRANSCEND-T2D-1 ✅ (Mar 2026) |
| SYNERGY | MASLD/MASH (liver disease) | None yet |
| TRIUMPH-Outcomes | Cardiovascular and renal outcomes (~10,000 participants) | None yet (multi-year) |
Sources: Eli Lilly investor relations (Dec 2025, March 2026), Lilly Medical (medical.lilly.com), ClinicalTrials.gov.
Is Retatrutide FDA-Approved, Legal, or Available Online?
No. Not any of those things.
Retatrutide has no FDA approval, no EMA approval, and no approval from any regulatory body in the world. Eli Lilly has not submitted a New Drug Application. The compound remains in Phase 3 clinical trials.
“Investigational” means it is being formally evaluated under FDA oversight. It is not banned — it is in the regulatory pipeline.
“Unapproved” means no doctor can prescribe it and no pharmacy can dispense it through normal channels.
“Illegal to sell” means any online vendor selling “retatrutide” or “retatrutide peptide” for human use is operating outside FDA regulations. The FDA has publicly warned against this. These products are not made by Eli Lilly, not subject to quality control, and may be contaminated, mislabeled, or inactive.
Can retatrutide be compounded?
No — and this is different from how semaglutide and tirzepatide have worked. Compounding pharmacies can legally prepare versions of FDA-approved drugs under specific regulatory conditions. Retatrutide has never been FDA-approved, so there is no legal basis for compounding it. The FDA has explicitly stated that retatrutide cannot be used in compounding under federal law. Any product marketed as “compounded retatrutide” is not a legitimate pharmaceutical product.
The only legitimate access
Enrollment in one of Eli Lilly's registered clinical trials on ClinicalTrials.gov. Search “retatrutide” or “LY3437943.” Eligibility varies by trial — BMI thresholds range from ≥23 to ≥30 depending on the study and population. Discuss with your healthcare provider.
If you want to start treatment now, the good news is that several excellent FDA-approved options exist today — and we cover them below.
What Are the Side Effects and Risks?
The side-effect profile shares a lot with other GLP-1 medications, but there is one finding that got outsized attention. Here is the full picture.
Common GI side effects (TRIUMPH-4 Phase 3)
| Side effect | Retatrutide 9 mg | Retatrutide 12 mg | Placebo |
|---|---|---|---|
| Nausea | 38.1% | 43.2% | 10.7% |
| Diarrhea | 34.7% | 33.1% | 13.4% |
| Constipation | 21.8% | 25.0% | 8.7% |
| Vomiting | 20.4% | 20.9% | 0.0% |
| Decreased appetite | 19.0% | 18.2% | 9.4% |
GI effects consistent with the GLP-1 drug class. Most occur during dose escalation and improve as the body adjusts. Source: Eli Lilly TRIUMPH-4 topline data, December 2025.
Dysesthesia — the finding that made headlines
Dysesthesia means abnormal skin sensation — tingling, numbness, pins-and-needles, or sensitivity to normal touch. In TRIUMPH-4:
- 20.9% of participants at 12 mg
- 8.8% at 9 mg
- 0.7% on placebo
When this number first appeared, many headlines framed it as uniquely alarming. The reality is more nuanced. On March 19, 2026 — the same day as the TRANSCEND-T2D-1 readout — the FDA approved Wegovy HD (semaglutide 7.2 mg). Its STEP UP trial reported altered skin sensations in 22% of participants at the 7.2 mg dose, compared to 6% at 2.4 mg and 0.3% on placebo. The FDA noted this in the Wegovy HD label.
This suggests dysesthesia may be a dose-dependent class effect that emerges at higher potencies across GLP-1 medications — not something exclusive to retatrutide's triple-agonist mechanism.
The 9 mg dose deserves attention.
The 9 mg dose produced 26.4% weight loss with a dysesthesia rate of 8.8% instead of 20.9%. For many people, trading 2.3 percentage points of weight loss for a substantially lower incidence of tingling would be a reasonable decision. Upcoming TRIUMPH data in 2026 will help clinicians optimize this tradeoff.
Discontinuation rates
In TRIUMPH-4, 12.2% (9 mg) and 18.2% (12 mg) of participants discontinued due to adverse events, compared to 4.0% on placebo. Notably, some discontinuations were attributed to “perceived excessive weight loss” — participants losing more than they expected. Discontinuation rates were lower in participants with higher baseline BMI.
How Does Retatrutide Compare to What Is Available Now?
The GLP-1 landscape in April 2026 is genuinely crowded with strong options. We assembled this comparison from published clinical trial data and current market information — each cell sourced separately.
| Semaglutide injection (Wegovy / Wegovy HD) | Tirzepatide (Zepbound) | Oral semaglutide (Wegovy pill) | Orforglipron (Foundayo) | Retatrutide | |
|---|---|---|---|---|---|
| Receptors | GLP-1 | GLP-1 + GIP | GLP-1 | GLP-1 | GLP-1 + GIP + Glucagon |
| Route | Weekly injection | Weekly injection | Daily pill (fasting required) | Daily pill (no food/water restrictions) | Weekly injection |
| Best weight loss in trials | 20.7% at 72 wks (Wegovy HD 7.2 mg, STEP UP) | ~22.5% at 72 wks (15 mg, SURMOUNT-1) | 16.6% at 64 wks (25 mg, OASIS 4) | 12.4% at 72 wks (highest dose, ATTAIN-1) | 28.7% at 68 wks (12 mg, TRIUMPH-4) |
| FDA status | ✅ Approved (HD: Mar 2026) | ✅ Approved 2023 | ✅ Approved Dec 2025 | ✅ Approved Apr 1, 2026 | ❌ Not approved |
| Available now? | Yes | Yes | Yes | Yes (via LillyDirect, expanding) | No — trials only |
| Self-pay price | ~$1,350/mo list | ~$1,060/mo list | ~$249–$329/mo (subscription) | $149/mo self-pay; $25/mo with insurance | Not announced |
Sources: STEP UP (Novo Nordisk, Mar 2026), SURMOUNT-1 (NEJM 2022), OASIS 4 (Novo Nordisk, Dec 2025), ATTAIN-1 (Lilly, Apr 2026), TRIUMPH-4 (Lilly, Dec 2025). Pricing from manufacturer announcements as of April 2026.
Critical caveat: No completed head-to-head trial has directly compared retatrutide against semaglutide or tirzepatide in the same study. Every cross-trial comparison is suggestive, not definitive — different populations, durations, and designs.
For more on how currently available providers compare on price and access, see our GLP-1 telehealth provider comparison. For a detailed breakdown on retatrutide versus semaglutide specifically, see Retatrutide vs. Semaglutide.
Should You Wait for Retatrutide or Start Something Available Now?
This is where the search ends. For most people, waiting for a drug that is not approved, has no confirmed filing date, and is realistically years from your pharmacy is not a plan — it is a delay.
“I'm just tracking the pipeline”
Smart approach. Bookmark this page. We update it within 72 hours of every major readout, and seven more are expected in 2026. The one to watch: TRIUMPH-1, the broad obesity trial that will form the backbone of Lilly's eventual FDA submission.
“I want to start losing weight — not wait until 2028”
Then you should look at what is available today. This is not settling — semaglutide and tirzepatide are genuinely effective medications with years of evidence. Tirzepatide (Zepbound) produces approximately 22.5% weight loss in trials. Wegovy HD (7.2 mg) just demonstrated 20.7%. These are real results available right now. The worst outcome here is someone who delays treatment for two years waiting for retatrutide when they could be making meaningful health progress today.
“I want FDA-approved brand-name medication”
Ro carries both Zepbound (tirzepatide) and Foundayo (orforglipron). Pricing starts at $39 for the first month, then as low as $74/month with an annual plan, with medication billed separately. If FDA-approved is your priority, Ro is worth exploring.
“I plateaued on my current GLP-1 and need something stronger”
This is the population where retatrutide may eventually matter most. In the meantime: Wegovy HD (7.2 mg) was specifically approved for patients who have tolerated the 2.4 mg dose and need additional weight reduction. If you are on semaglutide 2.4 mg and have plateaued, a dose increase to 7.2 mg is now a legitimate clinical option. Ask your prescriber.
If you want to explore all your current options side by side, we maintain a regularly updated comparison. Compare GLP-1 telehealth providers and current pricing →
“Price is my biggest concern”
Foundayo (orforglipron) starts at $149/month self-pay at the lowest dose, or as low as $25/month with commercial insurance. It is a daily pill with no injection required and no fasting restrictions. For people where cost is the primary barrier, this may be the most accessible entry point. Note that the compounded GLP-1 landscape has changed significantly — if you are considering a compounded option, verify the current regulatory status with the provider before purchasing. We cover the latest situation on our provider comparison page.
What We Actually Verified for This Page
| Source | What we checked |
|---|---|
| Eli Lilly official FAQ (lilly.com) | Drug status, mechanism, access, 'GLP-3' terminology |
| Eli Lilly investor releases (investor.lilly.com) | TRIUMPH-4 topline, TRANSCEND-T2D-1 topline, Foundayo approval |
| Lilly Medical (medical.lilly.com) | Trial program structure, study designs |
| FDA (fda.gov) | Approval status, compounding policy, Wegovy HD approval, Foundayo approval |
| Novo Nordisk press releases | Wegovy HD data, oral Wegovy data, CagriSema status |
| NEJM (Jastreboff et al., 2023) | Phase 2 obesity trial |
| Nature Medicine (Sanyal et al., 2024) | Phase 2 liver fat substudy |
| ClinicalTrials.gov | Trial registrations and enrollment |
| Ro pricing page (ro.co) | Current pricing for FDA-approved treatment |
Evidence tiers we used:
Peer-reviewed: Published in a journal with independent review (NEJM, Nature Medicine). Highest confidence.
Company topline Phase 3: Official press release with specific results. High confidence in accuracy, but methodology not yet independently reviewed.
Official FAQ / regulatory: Eli Lilly or FDA statements about status and access. Authoritative for what they cover.
Analyst estimate: Timeline projections based on standard review processes. Explicitly speculative.
What we chose not to claim:
- We did not state a specific FDA approval date. Lilly has not committed to one.
- We did not quote a retail price. None has been announced.
- We did not present Phase 3 topline results as peer-reviewed. They are not.
- We did not include customer testimonials. Retatrutide is investigational.
- We did not claim causal mechanisms for specific side effects where data only reports associations.
Update policy: Updated within 72 hours of any Lilly readout, FDA action, or major conference presentation. Monthly review during active Phase 3 readout period. Visible “Last verified” date at page top.
Frequently Asked Questions About Retatrutide
Is retatrutide FDA-approved?▾
Can you buy retatrutide online?▾
Is GLP-3 a real medical term?▾
How does retatrutide work?▾
What are the most common retatrutide side effects?▾
Is retatrutide better than semaglutide?▾
Is retatrutide better than tirzepatide?▾
When will retatrutide be available?▾
Can retatrutide be compounded?▾
How much weight have people lost in retatrutide studies?▾
Still not sure which GLP-1 program is right for you?
Take our free 60-second matching quiz. We'll ask about your goals, insurance, and preferences and show you which FDA-approved options fit — whether that is a brand-name injectable, the new oral pill, or a path through your insurance.
Takes 60 seconds · Free · No signup required